Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Neoplasms 1Gallbladder Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × ARRY-334543 × Clear all
NCT03130790 2022-02-15

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

ASLAN Pharmaceuticals

Phase 2/3 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03093870 2021-08-03

TreeTopp

ASLAN Pharmaceuticals

Phase 2/3 Completed
151 enrolled 18 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡